Event Details
Share
Description
In this 1-hour virtual seminar, Michelle Cardel, Ph.D., M.S., RD, FTOS, will discuss how incretin-based medications, including semaglutide and tirzepatide, are transforming the landscape of obesity treatment. Research shows that these medications result in approximately 15–21% body weight loss in 1 year. However, incretin-based medications were intended to serve as an adjunct to behavioral modification, rather than a replacement. The behavioral and nutritional needs of patients on incretin-based obesity medications are unique, requiring a tailored approach to ensure nutritional adequacy, minimize common side effects such as nausea and constipation, and maintain lean muscle mass during rapid weight loss. Comprehensive telehealth medical weight management programs, which integrate behavioral support, have demonstrated meaningful impacts on not just weight, but overall health. This presentation will review the latest research on how behavioral programs affect a variety of outcomes for patients on a GLP-1RA medication, including diet quality, physical activity, and quality of life.
About the Speaker
Michelle Cardel, Ph.D., M.S., RD, FTOS
Co-Director, Center for Integrative Cardiovascular and Metabolic Disease at University of Florida
Dr. Cardel is a nutrition scientist and registered dietitian who serves as a faculty member at the University of Florida, where she co-directs the Center for Integrative Cardiovascular and Metabolic Diseases. A Fellow of The Obesity Society, Dr. Cardel has authored over 130 publications in high-impact journals like JAMA, JAMA Pediatrics, AJCN, and Obesity. Her numerous accolades include the University of Alabama (UAB) Outstanding Woman Award, the Academy of Nutrition and Dietetics Excellence in Emerging Outcomes Research Award, UAB’s Young Alumni Rising Star Award, and The Obesity Society’s Practitioner of the Year Award for Excellence in Clinical Care and Management of Obesity.
If you have questions for the Dr. Cardel, please email them to ONPA@mail.nih.gov.
Individuals requiring Sign Language Interpreters or other reasonable accommodations to facilitate their participation in this event should contact Susan Holbrook at susan.holbrook@nih.gov at least five (5) days prior to the commencement of the event.